Building upon these findings, an ongoing Phase Ib/II clinical trial (NCT04524871) is currently evaluating the efficacy and safety of adding anti-IL-6 therapy to the treatment of unresectable HCC patients receiving Ate/Bev. Here, IL6 is linked to hepatocellular carcinoma.